Journal of Blood Medicine最新文献

{"title":"Subcutaneous Hematoma Elevates Plasma Levels of FDP and D-Dimer; an Analysis by Animal Model Experiments.","authors":"Takami Nakao, Yasuhide Kitazawa, Shiori Masuda, Naoki Hashimoto","doi":"10.2147/JBM.S479126","DOIUrl":"https://doi.org/10.2147/JBM.S479126","url":null,"abstract":"<p><strong>Purpose: </strong>Trauma-associated coagulopathy has been considered to develop as a result of increased fibrinolysis due to massive bleeding, tissue damage and hypoperfusion. However, it has not been investigated whether hematoma may cause trauma-associated coagulopathy. Using experimental animal model, we analyzed the effects of hematoma formation on coagulation and fibrinolysis parameters.</p><p><strong>Materials: </strong>Male Wistar rats were used for the studies.</p><p><strong>Methods: </strong>We made an animal model of subcutaneous hematoma without tissue injuries. This model can be categorised as a kind of trauma models. We created experimentally subcutaneous hematomas in test animals using blood collected from other animals. We performed blood sampling to measure blood cell counts and coagulation parameters from test animals at 1, 6, 24, 48 and 96 hours after hematoma generation. Blood samples were collected and immediately sent for measurement of CBC, Prothrombin, FDP, D-dimer, Fibrinogen, Antithrombin, AST and ALT. Furthermore, after 1, 24 and 48 hours, we performed dynamic evaluation of coagulation/fibrinolysis function using thromboelastometry method.</p><p><strong>Results: </strong>After the hematoma were created, FDP and D-dimer increased over time, and reached a plateau after 48 hours. During the period, there was no decrease in Fibrinogen and Antithrombin, and no thrombocytopenia occurred. Moreover, no obvious changes in coagulation/fibrinolysis function were observed employing thromboelastometry.</p><p><strong>Discussion: </strong>Elevated FDP and D-dimer after hematoma creation are assumed to be synthesized in the hematoma, not in the streaming blood. Thromboelastometry also shows that elevated levels of FDP and D-dimer are not caused by intravascular coagulation and subsequent fibrinolysis.</p><p><strong>Conclusion: </strong>The study showed that subcutaneous hematomas caused increases in FDP and D-dimer levels, without activating the blood coagulation/fibrinolysis system.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"557-564"},"PeriodicalIF":2.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker.","authors":"Abdalla Fadul, Elmustafa Abdalla, Anas Mohamed, Bashir Ali, Nusiba Elamin, Ahmed Abdelghafar Alsayed, Abdulrahman F Al-Mashdali, Kalpana Singh, Shehab F Mohamed","doi":"10.2147/JBM.S474393","DOIUrl":"10.2147/JBM.S474393","url":null,"abstract":"<p><strong>Background: </strong>Elevated vitamin B12 (B12) levels are linked to an increased risk of cancers, including hematological malignancies. This study focuses on the relationship between elevated B12 and myeloproliferative neoplasms (MPNs): Polycythemia Vera (PV), Primary Myelofibrosis (MF), Essential Thrombocytosis (ET), and Chronic Myeloid Leukemia (CML). Elevated B12 in MPNs is believed to arise from increased transcobalamin I (TCI) secretion by proliferating leukocytes, leading to higher serum levels. B12 may serve as a diagnostic and prognostic biomarker for these conditions. However, its sensitivity, specificity, and cutoff levels are unclear.</p><p><strong>Aim: </strong>To assess the prevalence of high B12 levels in MPN patients, determine the median levels, identify a diagnostic cutoff, and evaluate the sensitivity and specificity of B12 as a marker.</p><p><strong>Methods: </strong>Data were retrieved from the National Center for Cancer Care and Research in Doha, Qatar, for MPN patients from January 2016 to December 2022.</p><p><strong>Results: </strong>A total of 467 patients were included: 232 with CML, 98 with PV, 88 with ET, and 50 with MF. The majority were male (66%) and of Asian origin (56%), with a median age of 48.7 years. CBC results showed median hemoglobin of 9.2 g/dL, WBC count of 73 x 10^3/uL, and platelet count of 531 x 10^3/uL. Elevated B12 levels were found in 95 patients (20%): 71% CML, 14% PV, 10% MF, and 5% ET. Extreme elevations were seen in 59 patients. The mean B12 level decreased from 747.3 ± 686.5 pg/mL before treatment to 397.9 ± 343.7 pg/mL after one year (p=0.01). Median levels were 458 pg/mL (718) before treatment and 301 pg/mL (229) after. In the extreme high B12 group, the mean was 1722 pg/mL before and 677 pg/mL after treatment.</p><p><strong>Conclusion: </strong>Elevated B12 levels are associated with disease activity in CML. However, their role as a reliable marker for disease monitoring remains uncertain, and further studies are needed to confirm their utility for CML progression.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"549-556"},"PeriodicalIF":2.1,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11687131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Knowledge and Medication Adherence Among Patients Prescribed with Oral Anticoagulants in Atrial Fibrillation at a Tertiary Care Centre: A Cross Sectional Study.","authors":"Pooja Khanal, Durga Bista, Rojeena Koju Shrestha","doi":"10.2147/JBM.S493313","DOIUrl":"10.2147/JBM.S493313","url":null,"abstract":"<p><strong>Purpose: </strong>Atrial fibrillation (AF) being a prevalent cardiovascular condition globally, has an increased risk of stroke and other complications. The effective management of AF often involves the use of oral anticoagulants (OACs) to prevent thromboembolic events. This study aimed to evaluate anticoagulation knowledge and medication adherence in AF patients on OACs at a tertiary care center in Nepal.</p><p><strong>Patients and methods: </strong>A descriptive cross-sectional study involving patients diagnosed with AF who were prescribed OACs at the Cardiology Department of Dhulikhel Hospital, Nepal, was conducted from March to June 2024. Data were collected using questionnaires, including the Oral Anticoagulation Knowledge Tool (AKT) and the Adherence in Chronic Diseases Scale (ACDS). The study included patients from the Dhulikhel Atrial Fibrillation (DAF) Registry database along with other AF patients visiting the cardiac department. Descriptive statistics were used to summarize patient demographics, knowledge scores, and adherence levels. Inferential statistics were used to observe the associations.</p><p><strong>Results: </strong>Among the 114 AF patients enrolled in the study, 93 were receiving OAC therapy and were interviewed. The mean age of the participants was 66.84 ± 12.3 years, with the majority being female (57%). The study revealed that a significant portion of patients lacked adequate knowledge about their OAC therapy, with only 48% having adequate knowledge as per the AKT. Additionally, 83.9% of the patients demonstrated high adherence to their medication regimen, whereas 16.1% showed medium adherence. The duration of use of OACs was found to be significantly associated with adequate anticoagulation knowledge.</p><p><strong>Conclusion: </strong>The study findings indicate that a significant proportion of AF patients in Nepal lack adequate anticoagulation knowledge, highlighting an opportunity for improved educational interventions.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"533-547"},"PeriodicalIF":2.1,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder.","authors":"Etha Dini Widiasi, Pradana Zaky Romadhon, Ami Ashariati, Siprianus Ugroseno Yudho Bintoro, Muhammad Noor Diansyah, Putu Niken Ayu Amrita, Merlyna Savitri","doi":"10.2147/JBM.S482753","DOIUrl":"10.2147/JBM.S482753","url":null,"abstract":"<p><p>Gallbladder adenocarcinoma has a high mortality rate, with approximately 1.7% cancer-related deaths worldwide. Cancer-associated thrombosis (CAT), including deep vein thrombosis (DVT), can significantly increase the risk of mortality within cancer patients, especially in pancreatic, brain, and intra-abdominal cancers, as well as in advanced and metastatic cancers. In this case report, there was a 45-year-old male patient diagnosed with advanced gallbladder adenocarcinoma UICC stage IVB with a TNM stage of T2b, N0, M1 with liver metastases who experienced pain and swelling in both lower limbs after undergoing a VI-A cycle of chemotherapy with gemcitabine capecitabine. The risk of thrombosis was calculated using the modified Khorana-Vienna CAT scores, which increased during every chemotherapy session. In this case, the Khorana-Vienna CAT score was calculated during two latest cycle of chemotherapy that somewhat considered delayed as the patient had already shown hypercoagulopathy symptoms and developed a poorer prognosis. Early CAT scoring, ideally before starting chemotherapy session, potentially improves thrombosis prognosis. The patient's condition improved after administration of antithrombotic agents. Chemotherapy agents and other factors, including the cancer site and presence of metastatic cancer, influence the risk of CAT. Risk predictor scores are required to assess the risk of CAT and benefits of prophylactic treatment. Prophylactic therapy can be initiated in patients with high-risk CAT, calculated using the modified Khorana and Vienna CAT scores, to prevent thrombosis and improve patient outcomes.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"523-531"},"PeriodicalIF":2.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determine Complete Blood Count Reference Values Among Healthy Adult Populations.","authors":"Abdul Baset Abbas, Abeer Aldomaini, Amah Alrahman Al-Qadri, Zahra'a Algorbani, Sara Aljamali, Safa Alsiri, Khadeeja Alghorbani, Saba Abo Osba'a","doi":"10.2147/JBM.S488050","DOIUrl":"10.2147/JBM.S488050","url":null,"abstract":"<p><strong>Background: </strong>Complete blood counts (CBC) are commonly used in diagnostic medicine to evaluate normal and abnormal hematological status. Furthermore, reference values (RVs) of CBC supplied by researchers are the most reliable means of the judgment-making stage and can aid interpretation and accurate diagnosis of diseases. Reference values vary between peoples because of differences in lifestyle, dietary habits, ethnicity and environment. Moreover, the Clinical and International Standards Institute (CISI) advises determining the RVs for each area. There are no RVs for CBC in Yemen. Therefore, this study aimed to determine the common RVs of CBC for healthy adults in Ibb City in the middle of Yemen.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from April 1, to November 30, 2023. Of the 623 adults who participated in this study, 433 (aged 18-80 years) were included in the final analysis after applying exclusion criteria. The mean, median, and 95^th percentile RVs (2.5^th-97.5^th percentiles) were calculated for gender, age, and residence by the GraphPad Prism 8.0.1.</p><p><strong>Results: </strong>The RVs of hemoglobin (Hb) 11.16-17.54g/dl, red blood cells (RBC) 3.890-6.340×10¹²/l, hematocrit (HCT) 33.03-49.30%), mean corpuscular volume (MCV) 72.83-94.55fl), mean corpuscular hemoglobin (MCH) 23.95-33.55pg, mean corpuscular hemoglobin concentration (MCHC) 32.97-36.7354g/dl, platelet (PLT) count 140.0-418.6×10⁹/l, total white blood cells (WBC) 2.810-8.797 ×10⁹/l and WBC differential count (basophils 0.000-1.000%, neutrophils 30.10-69.17%, eosinophils 1.500-5.000%, lymphocytes 23.86-63.45% and monocytes1.873-5.600%). Significantly higher median values were observed in males compared to females for Hb (<i>P</i><0.0001), RBC (<i>P</i><0.0001), HCT (<i>P</i><0.0001), lymphocyte (<i>P</i>=0.0197) and monocytes (<i>P</i>=0.0009). Contrariwise, females demonstrated significantly higher neutrophils (<i>P</i>=0.0009), eosinophils (<i>P</i>=0.0020), basophils (<i>P</i><0.0001) and platelets (<i>P</i>=0.0324) than males. This study showed differences in the RVs of CBC compared to those reported in other countries in the Middle East, Asia, Africa, and Europe.</p><p><strong>Conclusion: </strong>In this study, the reference values of CBC are considered as a benchmark that may assist in accurately judging laboratory results and enhancing medical and clinical services for adults in Ibb City, Yemen.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"513-522"},"PeriodicalIF":2.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombotic Risk Assessment, P-Selectin, and Thromboprophylaxis Use Among, Cancer Patients at the University of Calabar Teaching Hospital, Calabar.","authors":"Kingsley Akaba, Edakabasi Akaba, Olukayode Oshatuyi, Brian Ssenkumba","doi":"10.2147/JBM.S478192","DOIUrl":"10.2147/JBM.S478192","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism is the second leading cause of mortality among cancer patients. The Khorana Risk Assessment Score (KRAS) is widely acknowledged as the most validated tool in this context.</p><p><strong>Aim: </strong>To assess the thrombotic risk in cancer patients using the modified Khorana Risk Assessment Score, examine the association between modified KRAS and soluble P-selectin levels, and document the utilization of thromboprophylaxis among cancer patients at the University of Calabar Teaching Hospital.</p><p><strong>Methods: </strong>This was a cross-sectional hospital-based recruiting 100 cancer patients. Seven millilitres of blood were collected for complete blood count and P-selectin assay. Continuous variables were expressed as mean and standard deviation, while categorical variables were summarized using frequencies. Chi-square was employed to compare VTE risk status across genders, different cancer types, and guideline compliance. The significance level was set at 0.05.</p><p><strong>Results: </strong>Participants age ranged from 19 to 87 years, with a male-to-female ratio of 1:1.6. The most common female cancer was Breast at 40.32% and prostate cancer at 65.79% was the most common in males. Seventy nine percent and 21% of participants had intermediate and high-risk modified KRAS scores respectively. The median level of soluble P-selectin among cancer patients was 23.00 within the interquartile range. Significant associations were observed between cancer types and sex, VTE risk assessment and cancer types, and cancer types and risk score.</p><p><strong>Conclusion: </strong>The risk of VTE among cancer patients ranges from intermediate to high, going by the modified Khorana risk score irrespective of the P selectin level, with underutilization of thromboprophylaxis. There is little adherence to the Khorana score in our setting, hence the need for greater application and knowledge of this predictive score in clinical practice to improve outcomes and quality of life.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"501-512"},"PeriodicalIF":2.1,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19-Associated Immune Thrombocytopenic Purpura in a Hemodialysis Patient.","authors":"Shuqin Mei, Cheng Xue, Zheng Zhang, Lingling Liu, Wenwen Cai, Xuelian Gong, Zhiguo Mao, Xiaojing Tang, Bing Dai","doi":"10.2147/JBM.S496127","DOIUrl":"10.2147/JBM.S496127","url":null,"abstract":"<p><strong>Background: </strong>Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection has been a global threat since the end of 2019. Although the main clinical manifestation of coronavirus disease 2019 (COVID-19) is respiratory, its range of clinical manifestation is extensive and may include various systems, including hematological disorders, such as lymphopenia, thrombotic events, thrombocytopenia and immune thrombocytopenic purpura (ITP). The present case was the first one that aimed to raise awareness of ITP induced by COVID-19 in patients undergoing maintenance hemodialysis.</p><p><strong>Case presentation: </strong>This is the case of a 75-year-old Asian woman who was diagnosed COVID-19 positive 15 days before attending our Emergency Department on January 19th, 2023, with a three-day history of severe bleeding symptoms, including gastrointestinal, mucosal bleeding, epistaxis, and the platelet count of 5×10⁹/L. She suffered from end-stage kidney disease due to autosomal dominant polycystic kidney disease and has received thrice-weekly maintenance hemodialysis (MHD) since 2012. Platelet count recovery was observed after 45 days of combined treatment with corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists, and rituximab. The count of platelets rose to 180×10⁹/L after four dosages of Rituximab.</p><p><strong>Conclusion: </strong>In brief, SARS-CoV-2 infection might trigger the onset of ITP. To our knowledge, this is the first case with severe and refractory ITP secondary to COVID-19 in MHD patients and no guidelines were able to be referred on the therapy. Nephrologists must be concerned with clinical characteristics, diagnostic flowcharts, and therapy for SARS-CoV-2-induced ITP.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"495-500"},"PeriodicalIF":2.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Donation: Fears and Myths in Healthcare Workers of the Future.","authors":"Maham Arshad, Ayesha Ellahi, Fahad Ahmed, Javaid Usman, Saleem Ahmed Khan","doi":"10.2147/JBM.S446697","DOIUrl":"https://doi.org/10.2147/JBM.S446697","url":null,"abstract":"<p><strong>Objective: </strong>To determine the fears and myths related to blood donation in future health care workers.</p><p><strong>Study design: </strong>Cross-sectional study.</p><p><strong>Place and duration of study: </strong>This study was carried out from October to December 2022 at the National University of Medical Sciences (NUMS), Rawalpindi, Pakistan. Donors were selected according to the, WHO recommended, Safe Blood Transfusion Program of Pakistan criteria.</p><p><strong>Results: </strong>In total, 411 participants were included in the study. The individuals were 21-24 years of age, with a mean age of 21 years. In our study, females dominated (232/411); the remaining 179 were males. Out of the total 411, 145 participants had previously donated blood while the other 266 had never donated blood. Our study analyzed both of these groups. The most common symptoms experienced by blood donors were dizziness, post-donation weakness, and bodily aches and pains. Most non-donors feared problems related to their general health (42.3%) and developing infections (12.7%). <i>P-</i>value was 0.002, which reveals a significant association between fears and intention to donate blood.</p><p><strong>Conclusion: </strong>These results suggest that fears and concerns related to blood donation play a leading role in forecasting donors' attitudes and intentions. Motivation leads to inspiration and potential donors can be motivated by addressing their fear.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"487-493"},"PeriodicalIF":2.1,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use and Effectiveness of Carboximaltose Iron in Preoperative Anemia Treatment: A Multicenter and Retrospective Study.","authors":"Angel Manuel Yuste Gutierrez, Marta Alonso-Moreno, Jose Luis Perez Blanco, David Berlana, Maria Angeles Peña Fernandez, Maria Teresa Perez Maroto, Miguel Torralba","doi":"10.2147/JBM.S460422","DOIUrl":"10.2147/JBM.S460422","url":null,"abstract":"<p><strong>Aim: </strong>Anemia, primarily due to iron deficiency, is a key risk factor in both elective and emergency surgeries. Immediate preoperative treatment with ferric carboxymaltose (FCM) in anemic patients can reduce the need for transfusions and the length of hospital stay, thereby optimizing surgical outcomes. The objective of this study was to assess the effectiveness and describe the use of administering intravenous FCM prior to elective scheduled surgery for patients diagnosed with anemia.</p><p><strong>Methods: </strong>Multicenter, retrospective cohort study that encompassed patients aged 18 years and older who underwent surgery between January 2017 and December 2018. Demographic variables, dose scheme, baseline and perioperative haemoglobin (Hb), transfusion requirements, and admission days were collected. The primary endpoints were the response rate and effectiveness of FCM, defined as the proportion of patients with Hb preoperative levels of ≥13 g/dL. A patient response was deemed to occur when Hb level increased by 1 g/dL or more. The secondary endpoints were the appropriateness of FCM dose, transfusion requirement rate, and length of hospital stay.</p><p><strong>Results: </strong>446 patients (55.2% women, median age 69 IQR:52-78 years) were included. The median total dose of FCM administered was 1000 mg over a span of 5 day (IQR: 0-16) days before surgery. 62.8% of patients received lower doses, 24.9% had an INCREASE of Hb ≥ 1 g/dL, 11.6% had Hb ≥ 13 g/dL and 21.3% required blood transfusions, with a mean of 0.73 units transfused. The length of the hospital stay was 12 days (IQR:6-23).</p><p><strong>Conclusion: </strong>Low percentage of patients achieved a hemoglobin level of 13 g/dL or experienced an increase in hemoglobin of 1 g/dL or more following the administration of FCM, indicating the low effectiveness of FCM in treating perioperative anaemia in our surgical patients. There is underdosing of FCM and insufficient time between FCM administration and surgery in most patients. Both transfused and non-transfused patients show similar Hb increases, while those receiving a standard 1000 mg dose of FCM experience shorter hospital stays compared to those receiving 500 mg, and patients with more transfusions have longer hospital stays.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"477-486"},"PeriodicalIF":2.1,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paving the Road for Haematopoietic Stem Cell Transplantation in the United Arab Emirates: A Single Centre's Experience.","authors":"Panayotis Kaloyannidis, Biju George, Ahmad Alrustamani, Charbel Khalil, Basmah Al-Charfli, Nour Al-Moghrabi, Dima Ibrahim, Mohammed Alfar, Mohammed Daryahya, Kayane Mheidly, Amro El-Saddik, Humaid O Al-Shamsi","doi":"10.2147/JBM.S468665","DOIUrl":"https://doi.org/10.2147/JBM.S468665","url":null,"abstract":"<p><strong>Background: </strong>Despite its long-term history, haematopoietic stem cell transplantation (HSCT) still faces challenges in several countries under development and especially in the private health sector.</p><p><strong>Objectives design and methods: </strong>In this retrospective analysis, we present our experience and the results of 48 adult patients who underwent HSCT (autologous 37, allogeneic 9) at a private-sector hospital in Abu Dhabi, United Arab Emirates (UAE). The main indications were multiple myeloma and acute myeloid leukaemia in the autologous and allogeneic setting, respectively.</p><p><strong>Results: </strong>All patients successfully engrafted, and after a median follow-up of 6 (range: 1-11) months, 42 patients are alive (36 autografted and 6 allografted). The 1-year overall survival rates were 97% and 62% for autografted and allografted patients, respectively, while 4 patients died within 100 days post-transplant from treatment-related causes (1 patient from the autografted group and 3 patients from the allografted group).</p><p><strong>Conclusion: </strong>Our data confirm that HSCT is a feasible, safe, and effective treatment approach, offering high success rates to UAE patients with haematological malignant diseases.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"471-475"},"PeriodicalIF":2.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}